Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This randomized phase III trial studies tipifarnib in treating patients with acute myeloid
leukemia (AML) in remission. Tipifarnib may stop the growth of cancer cells by blocking the
enzymes necessary for their growth. It is not yet known whether tipifarnib is more effective
than observation alone in preventing the recurrence of AML.